Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has demonstrated substantial weight loss and cardiometabolic benefits, raising the possibility of a paradigm shift in OSA management.<h4>Objective</h4>To critically evaluate whether tirzepatide may act as a disease-modifying therapy in obesity-related OSA beyond its effects on weight reduction.<h4>Methods</h4>A narrative review was conducted using PubMed, Scopus, and Web of Science up to January 2026. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.